Controlling Esophageal Cancer: A Collaborative Modeling Approach

控制食管癌:协作建模方法

基本信息

  • 批准号:
    9753971
  • 负责人:
  • 金额:
    $ 116.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-08-01 至 2022-07-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Controlling Esophageal Cancer: A Collaborative Modeling Approach. The ultimate goal of the proposed research project is to advance our understanding of esophageal cancer and the impact of cancer control interventions to diminish the burden of this disease. This will be accomplished through a collaborative and comparative modeling project. There are two main histologic types of esophageal cancer: adenocarcinoma (EAC) and Squamous Cell Carcinoma (ESCC). Although ESCC is more common globally, in the US and much of the western world, EAC is more common and of greater concern. Esophageal AdenoCarcinoma (EAC) has experienced a remarkable (more than 6-fold) increase in incidence over the past few decades, which is largely unexplained. To date, primary screening and prevention efforts have targeted patients with symptoms of gastroesophageal reflux disease (GERD) using endoscopy and biopsy to identify patients with Barrett's esophagus (BE), with BE patients targeted for endoscopic surveillance. There is no firm evidence indicating that this screening/surveillance strategy is effective, which is underscored by persistently poor survival rates while a large proportion of cancers continue to be diagnosed at late and invasive stages. With an estimated 40-60 million Americans with GERD and 3-12 million with BE, the management of patients who are at significantly increased risk of EAC has become an important public health issue. In addition to uncertain long-term benefits, current unproven strategies may subject patients to overtesting and overdiagnosis, negatively impacting patient quality of life while expending considerable medical resources. The research team's prior work includes comparative modeling of the natural history of EAC by three independent models providing a strong foundation upon which to perform analyses that assess and improve screening and prevention strategies: specifically, the evaluation of cutting-edge enhancements such as new screening technologies, prevention, genomic and other biomarkers, and clinical prediction tools. Precision risk stratification is the aim, with the broader goal to identify a caner control strategy that is effective while limiting overtesting and overtreatment, thereby reducing patient burden and improving healthcare efficiency. These modeling efforts will provide the personalized patient data necessary to construct a decision aid, which will minimize patient screening burden by aligning management choices with personal preferences for screening. Finally, although the initial focus of the project will be on EAC, ESCC is more common and widespread globally, particularly in parts of Asia such as China. The models will be extended to include an ESCC natural history component and assess ESCC screening in the US and China. The proposal will address the overarching goals of increasing our understanding of the natural history of esophageal cancer and determining the impact and of potential cancer control interventions with the ultimate goal of ameliorating cancer morbidity.
 描述(由应用程序提供):控制食管癌:一种协作建模方法。拟议的研究项目的最终目标是提高我们对食管癌的理解以及癌症控制干预措施减少该疾病燃烧的影响。这将通过协作和比较建模项目来完成。食管癌有两种主要的组织学类型:腺癌(EAC)和方形细胞癌(ESCC)。尽管ESCC在全球范围内更为普遍,在美国和西方世界的大部分地区,但EAC更为普遍,更加关注。在过去的几十年中,食道腺癌(EAC)的炎症增加了(超过6倍),这在很大程度上是出乎意料的。迄今为止,主要的筛查和预防工作针对患有胃食管反射症症状(GERD)的患者,使用内镜和活检来鉴定患有巴雷特食管(BE)的患者,其针对内窥镜监测的患者。没有牢固的证据表明这种筛查/监视策略是有效的,而生存率持续较差,而很大一部分癌症则在晚期和侵入性阶段继续被诊断出来。估计有400-6000万美国人患有GERD,而BE的3-1200万美国人的管理人员的管理大大增加了EAC的风险,已成为一个重要的公共卫生问题。除了不确定的长期福利外,当前未经证实的策略还可能使患者经过超过和过度诊断,同时同时对患者的生活质量产生负面影响。研究团队的先前工作包括三个独立模型对EAC自然历史的比较建模,这提供了一个强大的基础,以对评估和改进筛查和预防策略进行分析:具体来说,是对新筛查技术,预防,预防,基因组和其他生物标志物以及其他生物标志物以及临床预测工具等尖端增强功能的评估。精确风险分层是目标,其更广泛的目标是确定在限制过度限制和过度处理的同时有效的罐头控制策略,从而减少了患者伯恩恩并改善医疗保健这些建模工作将为构建决策提供必要的个性化患者数据,从而最大程度地减少患者筛查的筛查,从而使患者筛查与个人偏好的管理选择,以使其筛查。最后,尽管该项目的最初重点将放在EAC上,但ESCC在全球范围内更为普遍,尤其是在中国等亚洲部分地区。这些模型将扩展到包括美国和中国的ESCC自然历史组成部分和评估ESCC筛选。该提案将解决我们对食管癌自然史的理解,并确定潜在的癌症控制干预措施的总体目标,以减轻癌症发病率的最终目标。

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Patients With Adenocarcinoma of the Esophagus or Esophagogastric Junction Frequently Have Potential Screening Opportunities.
  • DOI:
    10.1053/j.gastro.2021.12.255
  • 发表时间:
    2022-04
  • 期刊:
  • 影响因子:
    29.4
  • 作者:
    Rubenstein JH;Evans RR;Burns JA;Arasim ME;Zhu J;Waljee AK;Harnessing Opportunities to Screen for Esophageal Adenocarcinoma Group
  • 通讯作者:
    Harnessing Opportunities to Screen for Esophageal Adenocarcinoma Group
The Race-Specific Incidence of Esophageal Squamous Cell Carcinoma in Individuals With Exposure to Tobacco and Alcohol.
接触烟草和酒精的个体食管鳞状细胞癌的种族特异性发病率。
  • DOI:
    10.1038/ajg.2016.346
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Prabhu,Anoop;Obi,Kenneth;Lieberman,David;Rubenstein,JoelH
  • 通讯作者:
    Rubenstein,JoelH
The Impact of the Policy-Practice Gap on Costs and Benefits of Barrett's Esophagus Management.
  • DOI:
    10.14309/ajg.0000000000000578
  • 发表时间:
    2020-07
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Omidvari AH;Roumans CAM;Naber SK;Kroep S;Wijnhoven BPL;Gaast AV;de Jonge PJ;Spaander MCW;Lansdorp-Vogelaar I
  • 通讯作者:
    Lansdorp-Vogelaar I
Proton Pump Inhibitors and Dementia Incidence.
质子泵抑制剂和痴呆症发病率。
  • DOI:
    10.1001/jamaneurol.2016.1962
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    29
  • 作者:
    Nguyen,Long;Hur,Chin
  • 通讯作者:
    Hur,Chin
Estimates and predictors of health care costs of esophageal adenocarcinoma: a population-based cohort study.
  • DOI:
    10.1186/s12885-018-4620-2
  • 发表时间:
    2018-06-27
  • 期刊:
  • 影响因子:
    3.8
  • 作者:
    Thein HH;Jembere N;Thavorn K;Chan KKW;Coyte PC;de Oliveira C;Hur C;Earle CC
  • 通讯作者:
    Earle CC
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chin Hur其他文献

Chin Hur的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chin Hur', 18)}}的其他基金

Domain-Knowledge Informed Deep Learning for Early Detection of Pancreatic Cancer
基于领域知识的深度学习用于胰腺癌的早期检测
  • 批准号:
    10458067
  • 财政年份:
    2021
  • 资助金额:
    $ 116.31万
  • 项目类别:
Comparative modeling of gastric cancer disparities and prevention in the US and globally
美国和全球胃癌差异和预防的比较模型
  • 批准号:
    10330855
  • 财政年份:
    2021
  • 资助金额:
    $ 116.31万
  • 项目类别:
Optimal Colorectal Cancer Surveillance Strategy for Lynch Syndrome by Genotype
按基因型分类的林奇综合征最佳结直肠癌监测策略
  • 批准号:
    10674701
  • 财政年份:
    2021
  • 资助金额:
    $ 116.31万
  • 项目类别:
Comparative modeling of gastric cancer disparities and prevention in the US and globally
美国和全球胃癌差异和预防的比较模型
  • 批准号:
    10705668
  • 财政年份:
    2021
  • 资助金额:
    $ 116.31万
  • 项目类别:
Optimal Colorectal Cancer Surveillance Strategy for Lynch Syndrome by Genotype
按基因型分类的林奇综合征最佳结直肠癌监测策略
  • 批准号:
    10458721
  • 财政年份:
    2021
  • 资助金额:
    $ 116.31万
  • 项目类别:
Optimal Colorectal Cancer Surveillance Strategy for Lynch Syndrome by Genotype
按基因型分类的林奇综合征最佳结直肠癌监测策略
  • 批准号:
    10298217
  • 财政年份:
    2021
  • 资助金额:
    $ 116.31万
  • 项目类别:
Domain-Knowledge Informed Deep Learning for Early Detection of Pancreatic Cancer
基于领域知识的深度学习用于胰腺癌的早期检测
  • 批准号:
    10317236
  • 财政年份:
    2021
  • 资助金额:
    $ 116.31万
  • 项目类别:
A Personalized Approach to Targeted Esophageal Cancer Screening
针对性食管癌筛查的个性化方法
  • 批准号:
    10212990
  • 财政年份:
    2020
  • 资助金额:
    $ 116.31万
  • 项目类别:
A Personalized Approach to Targeted Esophageal Cancer Screening
针对性食管癌筛查的个性化方法
  • 批准号:
    10661535
  • 财政年份:
    2020
  • 资助金额:
    $ 116.31万
  • 项目类别:
A Personalized Approach to Targeted Esophageal Cancer Screening
针对性食管癌筛查的个性化方法
  • 批准号:
    10413908
  • 财政年份:
    2020
  • 资助金额:
    $ 116.31万
  • 项目类别:

相似国自然基金

去势环境下CAF来源的CREB3L4通过增强癌细胞脂肪酸合成促进前列腺癌转移的机制研究
  • 批准号:
    82303434
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
EZH2巴豆酰化修饰抑制乳腺癌细胞转移的作用和机制研究
  • 批准号:
    82372992
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
AR-MAX复合体调控前列腺癌细胞的转录抑制机制研究
  • 批准号:
    82303053
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于脂肪细胞对乳腺癌细胞的代谢重编程作用探讨3-羟基丁酰化修饰调控三阴性乳腺癌化疗敏感性的机制
  • 批准号:
    82303592
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
抑制MRPS21协同Bcl-xL抑制剂诱导前列腺癌细胞合成致死的分子机制研究
  • 批准号:
    82303033
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Mechanisms of Serrated Colon Tumor Suppression
锯齿状结肠肿瘤抑制机制
  • 批准号:
    10681608
  • 财政年份:
    2023
  • 资助金额:
    $ 116.31万
  • 项目类别:
Research Project Pancreatic Cancer
胰腺癌研究项目
  • 批准号:
    10715023
  • 财政年份:
    2023
  • 资助金额:
    $ 116.31万
  • 项目类别:
Advancing Systematic Delivery of Oncolytic Adenovirus for Pancreatic Cancer
推进溶瘤腺病毒治疗胰腺癌的系统递送
  • 批准号:
    10734709
  • 财政年份:
    2023
  • 资助金额:
    $ 116.31万
  • 项目类别:
Develop Conditionally Armored CAR Macrophage Therapy for Pancreatic Cancer
开发针对胰腺癌的条件装甲 CAR 巨噬细胞疗法
  • 批准号:
    10710883
  • 财政年份:
    2023
  • 资助金额:
    $ 116.31万
  • 项目类别:
CAR T cells targeting mesothelin and secreting bispecific antibodies targeting fibroblasts in pancreatic cancer
CAR T 细胞靶向间皮素并分泌靶向胰腺癌成纤维细胞的双特异性抗体
  • 批准号:
    10731635
  • 财政年份:
    2023
  • 资助金额:
    $ 116.31万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了